About Us

We bring together a group of researchers from Massachusetts General Hospital and Harvard Medical School.

Our researchers are…

Merging AI and Imaging

We are using the combined power of AI and imaging for biomarker discovery and improving population health,

Utilizing Multisystem Imaging

We are using multisystem imaging to learn how external stress leads to brain activation that advances atherosclerosis,

Addressing Cardiovascular Risk

We are addressing the excess risk of cardiovascular disease among patients with cancer,

Leveraging Advanced Imaging

We are leveraging advanced cardiac imaging for early and late phase clinical studies.

Our goal is to perform research that is uniquely impactful and potentially could affect patient care and clinical practice. As such, we thrive to break down silos and cross boundaries. We are asking the difficult questions for today’s major healthcare problems: Are there mechanistically sound pathophysiological pathways that explain novel insights? Do new markers have the potential to improve health outcomes in an economically viable fashion?

For this, we are pioneering multisystem imaging biomarker discovery – from coronary atherosclerosis to vascular inflammation to amygdala activity to myocardial fibrosis to deep learning based biological age – and conducting benchmark clinical trials – Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), myocardial fibrosis and function after anthracyclines using MR (STOP-CA), the effect of methotrexate on vascular inflammation with PET in HIV (CIRT PET sub-study), the effect of statins on myocardial fibrosis and fat in HIV (REPRIEVE-MR), and the effect of novel immune therapies for cancer on cardiovascular structure and function.